Criteria for the choice and monitoring of Menopausal Hormone Therapy

Abstract

To review the criteria for the selection of estrogens and especially progestogens for optimizing Menopausal Hormone Therapy (MHT). The main criteria are primarily derived from the Women's Health Initiative (WHI)-trial, disclosing the main risks like endometrial cancer, coronary heart disease (CHD), stroke, venous tromboembolism (VTE) and breast cancer. In addition observational studies must be considered for individualizing MHT, because WHI has tested only one preparation and has a lot of problems like early opening of the hormone/placebo-code (i.e., loss of placebo control), in 60% MHT-initiation too late, and in 40% risk factors for cardiovascular diseases and breast cancer. Pharmacological properties should be considered, such as only oral, but not transdermal estradiol increases VTE-risk. The choice of progestogens could be dependent on the different "partial effects" on steroid receptors, e.g., use of anti-androgenic progestogens in metabolic syndrome, Polycystic Ovary Syndrome (PCOS) etc., taking advantage of the anti-mineralocorticoid effect of drospirenone to stabilize blood pressure and reduce the risk of stroke, selection of tibolone for patients with sexual dysfunctions because its androgenic properties etc. Most important for the selection of the progestogen is endometrial efficacy, primary indication for progestogens in MHT. Therefore regular endometrial monitoring is reommended, using sequential or continuous combined regimens; "hormonal curettage" and/or the progestogen challenge text to avoid endometrial hyperproliferation. Levonorgestrel-IUD as progestogen component can reduce progestogen-dependent risks, offering also contraception, but often with longer bleeding problems, in contrast to sequential regimens of MHT, which can be used to treat irregular bleedings. Other main indications are treatment of climacteric complaints and prevention of osteoporosis and possible other preventive options. Regarding contraindications, according to the general rules of "class-labeling", they are the same for every MHT despite there are differences in benefits and risks. Choice of the timing of MHT-initiation is crucial to whether cardiovascular prevention (early start) or (like in WHI) increased risk of CHD and stroke occurs. The increased risk of breast cancer can be reduced using progesterone or its isomer dydrogesterone. Since, however, this risk cannot been excluded with any MHT, recommendations for screening on the possible development of breast cancer are given, on the basis of own recent research. Criteria for the selection of MHT are mainly to reduce possible risks as seen in WHI since for every MHT efficacy is good and essentially the same. Often the best choice is estradiol combined with progesterone or dydrogesterone, but also other progestogens should be considered including LNG-IUD, to optimize and individualize MHT.

References

[1] Asi N, Mohammed K, Haydour Q, Gionfriddo MR, Vargas OLM, Prokop LJ, Faubion SS, Murad MH. Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis. Systematic Reviews 2016;5:121–129.

[2] Baber RJ, Panay N, Fenton A, Group IMS. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric, 2016, 19: 109-150

[3] BarlowDH. Menopause and HRT–the state of the art in Europe. Maturitas, 2005, 51: 40-47

[4] Boardman HMP, Hartley L, Eisinga A et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane review. Cochrane Library 2015, Issue 3 Hormone therapy. http://www.thecochranelibrary.com

[5] BortolettoCC, BaracatEC, GonçalvesWJ, LimaGR, StávaleJN. Transvaginal ultrasonography and the progestogen challenge test in postmenopausal endometrial evaluation. Int J Gynaecol Obstet, 1997, 58: 293-298

[6] Canonico M, Carcaillon L, Plu-Bureau G, Oger E, Singh-Manoux A, Tubert-Bitter P, Elbaz A, Scarabin PY. Post menopausal hormone therapy and risk of stroke. Impact of the route of estrogen administration and type of progestogen. Stroke 2016;47:1734–1741.

[7] BruyniksN, BigliaN, PalaciosS, MueckAO. Systematic indirect comparison of ospemifene versus local estrogens for vulvar and vaginal atrophy. Climacteric, 2017, 20: 195-204

[8] Canonico M, Fournier A, Carcaillon L et al. Post menopausal hormone therapy and risk of idiopathic venous thromboembolism. Results from the E3N Cohort Study. Arterioscl Thromb Vasc Biol 2010; 30:340–345.

[9] Canonico M, Oger E, Plu-Bureau G et al. Hormone therapy and venous thromboembolism among postmenopausal women. Impact of the route of estrogen administation and progestogens: ESTHER Study. Circulation 2007;115:840–845.

[10] CanonicoM, Plu-BureauG, LoweGDO, ScarabinP-Y. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: a systematic review and meta-analysis. BMJ, 2008, 336: 1227-1231

[11] ChlebowskiRT, AndersonGL, AragakiAK, et al. . Association of Menopausal Hormone Therapy with breast cancer incidence and mortality during long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials. JAMA, 2020, 24: 369-380

[12] Chlebowski RT, Hendrix SL, Langer et al. (WHI Investigators). Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: Women's Health Initiative Randomized Trial. JAMA 2003;289:3243–53.

[13] Collaborative Group on Hormonal Factors in breast Cancer. Type and timing of hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet, 2019, 394: 1159-1168

[14] Cordina-Duverger E, Truong T, Anger A, et al. Risk of breast Cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France. PLOS One 2013; 11: 1–9, Nov e78016

[15] Cummings SR, Ettinger B, Delmas PD, et al; LIFT Trial Investigators. The effects of tibolone in older postmenopausal women. N Engl J Med. 2008;359:697–708

[16] Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008a;107:103–11.

[17] Fournies A, Fabre A, Mesrine S, et al. Use of different postmenopausal hormone therapies and risk of histology- and hormone-receptor-defined invasive breast cancer. J Clin Oncology. 2008b;26:1260–8.

[18] GambrellRD Jr. Use of progestogen therapy. Am J Obstet Gynecol, 1987, 156: 1304-1313

[19] GambrellRD Jr, MasseyFM, CastanedaTA, UgenasAJ, RicciCA, WrightJM. Use of the progestogen challenge test to reduce the risk of endometrial cancer. Obstet Gynecol, 1980, 55: 732

[20] GenazzaniA, PanayN, SimonciniT, et al. . Purified and specific cytoplasmic pollen extract: a non-hormonal alternative for thetreatment of menopausal symptoms. Gynecol Endocr, 2020, 36: 190-196

[21] Genazzani AR, Montelone P, Gianni A, Simoncini T. Hormone therapy in the postmenopausal years: considering benefits and risks in clinical practice. Human Reprod Update 2021;1115–1150.

[22] GlazierG, BowmanMA. A review of the evidence for the use of phytoestrogens as a replacement for traditional estrogen replacement therapy. Arch Intern Med, 2001, 161: 1161-1172

[23] GoldsteinSR, LumsdenMA. Abnormal uterine bleedings in perimenopause. Climacteric, 2017, 20: 440-420

[24] Grossman DC, Curry SJ, Owens DK, et al. US Preventive Services Task Force. Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: US Preventive Services Task Foce Recommendation Statement. JAMA 2017;318:2224–33.

[25] HamptonNR, ReesMC, LoweDG, RauramoI, BarlowD, GuillebaudJ. Levonorgestrel intrauterine system(LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women. Human Reprod, 2005, 20: 2653-2660

[26] HendersonVW. Hormone therapy and Alzheimer's disease: benefit or harm?. Expert Opin Pharmacotherapy, 2004, 5: 389-406

[27] Hodis HN, Mack WJ, Henderson VW, ELITE Research Group, et al. Vascular effects of early vs late postmenopausal treatment with estradiol. N Engl J Med 2016;374:1221–1231.

[28] https://doi.org/10.15761/CRT.1000239; NLM ID 1016 60517

[29] InvestigatorsWHI. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA, 2002, 288: 321-333

[30] JordanV. The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer. Endocr Relat Cancer, 2015, 22: R1-31

[31] KenemansP. EDITORIAL: Women's Health after WHI. Maturitas, 2005, 51: 1-3

[32] KenemansP, BundredNJ, FoidartJM, et al. . Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomized, non-inferiority trial. Lancet Oncol, 2009, 10: 135-146

[33] KrattenmacherR. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception, 2000, 62: 29-38

[34] KrebsEE, EnsrudKE, MacDonaldR, WiltTJ. Phytoestrogens for treatment of menopausal symptoms: a systematic review. Obstet Gynecol, 2004, 104: 824-836

[35] Kenemans P, Speroff L. Clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas 2005; 51: 21–28

[36] KuhlH. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric, 2005, 8(Suppl. 1): 3-63

[37] LangerRD. The evidence base for HRT: what can we believe?. Climacteric, 2017, 20: 91-96

[38] L'HermiteM, SimonciniT, FullerS, et al. . Could transdermal estradiol+progesterone be a safer postmenopausal HRT?. A Review Maturitas, 2008, 60: 185-201

[39] LippertTH, SeegerH, MueckAO. Clinical and pharmacological characteristics of the conjugated equine estrogens. Drug Therapy, 1999, 17: 362-364

[40] LoboRA, ArcherDF, KaganR, et al. . A 17b-estradiol-progesterone oral capsule for vasomotor symptoms in postmenopausal women: a randomized controlled trial. Obstet Gynecol, 2018, 132: 161-170

[41] LokkegardE, NielsenLH, KeidingN. Risk of stroke with various types of menopausal hormone therapies. Stroke, 2017, 48: 2266-2269

[42] LyytinenH, PukkalaE, YlikorkalaO. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol, 2009, 113: 65-73

[43] MansonJE, KaunitzAM. Menopause management - Getting clinical care back on track. N Engl J Med, 2016, 374: 803-806

[44] MansonJE, AragakiAK, RossouwJE, et al. . Menopausal Hormone Therapy and long-term all-cause and cause-specific mortality: The Women's Health Initiative Randomized Trials. JAMA, 2017, 318: 927-938

[45] MendelsohnME, KarasRH. The protective effects of estrogen on the cardiovascular system. N Engl J Med, 1999, 340: 1801-1811

[46] Maraghy MA, Badawy N, Wafa GA, N Bishai N. Progesterone challenge test in postmenopausal women at high risk. Maturitas 1994;19:53–57.

[47] MikkolaTS, ClarksonTB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res, 2002, 53: 605-619

[48] MikkolaTS, TuomikowskiP, LyytinenH, et al. . Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality. Menopause, 2015, 22: 976-983

[49] MueckAO. Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone. Climacteric, 2012, 15(Suppl 1): 11-17

[50] Mueck AO, Römer T. Choice of progestogen for endometrial protection in combination with transdermal estradiol in menopausal women. Horm Mol Biol Clin Investig (HMBCI) 2018 Jul 31;37(2). pii: /j/hmbci.2019.37.

[51] Mueck AO, Seeger H. Shapiro S. Risk of breast cancer during hormone replacement therapy: Mechanisms. Horm Mol Biol Clin Invest (HMBCI) 2010;3:329–339.

[52] MueckAO, RuanX. Oral contraception for women of middle age. Maturitas, 2015, 82: 266-270

[53] Mueck AO, Ruan X. EDITORIAL: Will estradiol/progesterone capsules for oral use become the best choice for menopausal hormone therapy? Climacteric. 2019b;22:535–7.

[54] MueckAO, SeegerH. Effect of hormone therapy on BP in normotensive and hypertensive women. Maturitas, 2004, 49: 189-203

[55] MueckAO, GenazzaniAR, SamsioeG, Vukovic-WysockiI, SeegerH. Low-dose continuous combinations of hormone therapy and biochemical markers for vascular tone and inflammation: Transdermal versus oral application. Menopause, 2007, 14: 978-984

[56] MueckAO, RuanX, PrasauskasV, GrobP, OrtmannO. Treatment of vaginal atrophy with estriol and lactobacilli combination: a clinical review. Climacteric, 2018, 21: 140-147

[57] Mueck AO, Ruan X. Vascular effects of progestogens. In: ISGE Series Frontiers in Gyn.Endocrinology (Editor Andrea R.Genazzani) Vol.6. Sex steroids' effects on brain, heart and vessels. Springer New York 2019a:197–208

[58] Mueck AO (on behalf of 10 German gynecological-endocrinological societies). Application recommendations for hormone substitution in the climacteric and postmenopause. Frauenarzt 2015;56:657–60.

[59] Mueck AO, Seeger H. Invited EDITORIAL. Estrogen as new option for prevention and treatment of breast cancer – does this need a "time-gap"? Climacteric 2015; 18: 444–447

[60] MueckAO, SeegerH, BühlingKJ. Use of dydrogesterone in hormone replacement therapy. Maturitas, 2009, 65(Suppl 1): S51-S60

[61] NAMS. Management of symptomatic vulvovaginal atrophy, . position statement of The North American Menopause Society. Menopause, 2013, 2013(20): 888-902

[62] NAMS. Nonhormonal management of menopause-associated vasomotor symptoms, . position statement of The North American Menopause Society. Menopause, 2015, 2015(22): 1155-1172

[63] Neves-E-CastroM, BirkhauserM, SamsioeG, et al. . EMAS position statement: the ten point giude to the integral management of menopausal health. Maturitas, 2015, 81: 88-92

[64] OelkersWH. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy. Climacteric, 2005, 8(Suppl 3): 19-27

[65] Ortmann O (on behalf of 19 German societies). German S3 Guideline on HRT. Hormonal Therapy in Peri- and Postmenopause. Short version of interdisciplinary S3 guideline. Frauenarzt 2009;10: 840–851.

[66] PalaciosS, Castelo-BrancoC, CurrieH, et al. . Update of management of genitourinary syndrome of menopause. A Practical Guide Maturitas, 2015, 82: 308-313

[67] PanayN, AndersonRA, NappiRE, et al. . Premature ovarian insufficiency: an International Menopause Society white paper. Climacteric, 2020, 23: 426-446

[68] Price T. EDITORIAL. Progesterone receptor membrane component 1: is the metabolism integral to its function and what other steroids are involved. Menopause 2013;20:486–487.

[69] PEPI trial Writing Group. Effects of Hormone Replacement Therapy on endometrial histology in postmenopausal women. JAMA, 1996, 275: 370-375

[70] PickarJH, ArcherDF, GoldsteinSR, et al. . Uterine Bleeding with Hormone Therapies in Menopausal Women: a Systematic Review, 2020, 23: 550-558

[71] PinkertonJV, Sanchez AguirreF, BlakeJ, et al. . The 2017 hormone therapy position statement of The North American Menopause Society. Menopause, 2017, 24: 728-753

[72] PourhadiN, MørchLS, HolmEA, Torp-PedersenC, MeaidiA. Menopausal hormone therapy and dementia: nationwide, nested case-control study. BMJ, 2023, 28(381) e072770

[73] QinY, RuanX, JuR, PangJ, ZhaoG, HuX. Acupuncture for menopause symptoms in Chinese women: a systematic review. Climacteric, 2021, 24: 68-73

[74] Rahn DD, Carberry C, Sanses TV, et al. Society of Gynecologic Surgeons Systematic Review Group. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol 2014;124:1147–56

[75] Renoux C, Dell-Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thrombosis Haemostasis. 2010a;8:979–86.

[76] Renoux C, Dell’Aniello S, Garbe D, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ. 2010b;3(340): c2519. https://doi.org/10.1136/bmj.c2519.

[77] Ruan X, Li M, Mueck AO. Why Polycystic Ovary Syndrome (PCOS) needs long-term management?Current Pharmaceutical Design 2018;24: 4685–4692.

[78] RuanX, MueckAO. Systemic progesterone therapy: oral, vaginal, injections and even transdermal?. Maturitas, 2014, 79: 248-255

[79] RuanX, MueckAO. Impact of smoking on estrogenic efficacy. Climacteric, 2015, 18: 38-46

[80] Ruan X, Mueck AO. Primary choice of estrogen and progestogen as components for HRT - a clinical pharmacological view. Climacteric. 2022b;25:443–52.

[81] RuanX, MueckAO. The WHO claims estrogens are "carcinogenic": Is this true?. Climacteric, 2023, 26: 263-270

[82] RuanX, SeegerH, MueckAO. The pharmacology of dienogest. Maturitas, 2012, 71: 337-344

[83] RuanX, SeegerH, MueckAO. The pharmacology of nomegestrol acetate. Maturitas, 2012, 71: 345-353

[84] RuanX, KubbaA, AguilarA, MueckAO. Use of cyproterone acetate/ethinylestradiol in polycystic ovary syndrome: rationale and practical aspects. Europ J Contraception Reprod Health Care, 2017, 22: 183-190

[85] RuanX, ZhangY, MueckAO, et al. . Increased expression of progesterone membrane component 1 is associated with aggressive phenotype and poor prognosis in ER-positive and –negative breast cancer. Menopause, 2017, 24: 203-209

[86] RuanX, CaiG, WeiY, GuM, ZhangY, ZhaoY, MueckAO. Association of circulating Progesterone Receptor Membrane Component-1 (PGRMC1) with breast tumor characteristics and comparison with known tumor markers. Menopause, 2020, 27: 183-193

[87] Ruan X, Mueck AO, Beer AM, Naser B, Pickartz S. Benefit–risk profile of black cohosh (isopropanolic Cimicifuga racemosa extract) with and without St.John’s wort in breast cancer patients. Climacteric 2019; 22: 339–347

[88] Ruan X, Mueck AO. Clinical importance of PGRMC1 in hormone responsive breast cancer. Breast Care 2022a; published online Nov 8, 2022; https://doi.org/10.1159/000527969

[89] Ruan X, Mueck AO. Hormonal treatment of vulvar vaginal atrophy (VVA): Are there options to reduce or avoid systemic adverse effects and risks? Clin Res Trials 2018; 4(6):1–9; open access; online ISSN: 2059–0377;

[90] SantenRJ, AllredDC, ArdoinSP, et al. . Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab, 2010, 95(Suppl 1): s1-s66

[91] Sarri G, Davies M, Lumsden MA. Guideline Development Group. Diagnosis and management of menopause: summary of NICE guidance. BMJ 2015; 351:h5746; http://www.ncbi.nlm.nih.gov/pubmed/26563259.

[92] ScarabinPY, OgerE. Plu-Bureau G (for the ESTHER Study Group): Differential association of oral and transdermal oestrogen replacement therapy with venous thromboembolism risk. Lancet, 2003, 362: 428-432

[93] SchindlerAE, CampagnoliC, DruckmannR, HuberJ, PasqualiniJR, SchweppeKW, ThijssenJHH. Classification and pharmacology of progestins. Maturitas, 2003, 46: S7-S16

[94] SchlaffWD, CoddingtonCC. Use of the progestin challenge test in diagnosing amenorrhea: the time has come to say goodbye. Fertil Steril, 2020, 113: 51-52

[95] SchneiderC, JickSS, MeierCR. Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations. Climacteric, 2009, 12: 514-524

[96] Schierbeck LL, Rejnmark L, Landbo et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012;345:e6409.

[97] SeegerH, MueckAO. Effects of dydrogesterone on the vascular system. Gynecol Endocrinology, 2007, 23(S1): 2-8

[98] Service RF. New role of estrogen in cancer. Science, 1998, 279: 1631-1637

[99] Simon JA1, Laliberté F, Duh MS, Pilon D, Kahler KH, Nyirady J, Davis PJ, Lefebvre P. Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy. Menopause 2016;23:600–610.

[100] SperoffL. Transdermal hormone therapy and the risk of stroke and venous thrombosis. Climacteric, 2010, 13: 429-432

[101] Stanczyk FZ. EDITORIAL. Can the increase in breast cancer observed in the estrogen plus progestin arm of the Women's Health Initiative trial be explained by progesterone receptor membrane component 1? Menopause 2011;18:833–834.

[102] Stanczyk FZ, Hapgood JP, Winer S, and Daniel R. Mishell Jr. DR. Progestogens used in post menopausal hormone therapy: Differences in their pharmacological properties, intracellular actions, and clinical effects. Endocrine Rev 2013; 34:171–208.

[103] Stefanick ML, Anderson GL, Margolis KL et al. (WHI Investigators). Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647–57.

[104] StevensonJC, FarmerRDT. HRT and breast cancer: a million-women study ride again. Climacteric, 2020, 23: 226-228

[105] SturdeeDW, PanayN. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric, 2010, 13: 509-522

[106] StuteP, WildtL, NeulenJU. The impact of micronized progesterone on breast cancer risk: a systematic review. Climacteric, 2018, 21: 111-122

[107] Stute P, Neulen J, Wildt L. The impact of micronized progesterone on the endometrium:a systematic review. Climacteric. 2016;19:316–28.

[108] Tepper NK, Whiteman MK 2, Marchbanks PA, James AH, Curtis KM. Progestin-only contraception and thromboembolism: A systematic review. Contraception 2016;94:678–700.

[109] Suvanto-LuukkonenE, KauppilaA. The levonorgestrel intrauterine system in menopausal hormone replacement therapy: five-year experience. Fertil Steril, 1999, 72: 161-163

[110] VarilaE, WahlströmT, RauramoI. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. Fertil Steril, 2001, 76: 969-973

[111] VenetkoskiMM, Savolainen-PeltonenHM, Rahkola-SoisaloPK, et al. . Increased cardiac and stroke death risk in the first year after discontinuation of postmenopausal hormone therapy. Menopause, 2018, 25: 375-379

[112] VilliersT, HallJE, PinkertonJ, Cerdas PerezS, ReeseM, YangC, PierroDD. Revised global consensus statement on menopausal hormone therapy. Climacteric, 2016, 19: 313-315

[113] WHI Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA, 2004, 291: 1701-1712

[114] WhiteWB. Drospirenone with 17beta-estradiol in the postmenopausal woman with hypertension. Climacteric, 2007, 10(Suppl 1): 25-31

[115] WiebeJP, LewisMJ, CialacuV, PawlakKJ, ZhangG. The role of progesterone metabolites in breast cancer: Potential for new diagnostics and therapeutics. J Steroid Biochem Mol Biol, 2005, 93: 201-208

[116] Zhang J, Li Y, Zhang B, Chen K et al; academic committee of Evidence-Based Chinese Medicine panel of the 12th Health China Forum. Evidence-based traditional Chinese medicine research: Beijing Declaration. J Evid Based Med. 2020;13:91–92.

RIGHTS & PERMISSIONS

The Author(s)